Beyond The Numbers: 11 Analysts Discuss Ardent Health Stock
Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Ardent Health (NYSE:ARDT) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 4 | 3 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 2 | 3 | 1 | 1 | 0 |
Analysts have set 12-month price targets for Ardent Health, revealing an average target of $13.18, a high estimate of $17.00, and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.2%.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Ardent Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Benjamin Rossi | JP Morgan | Lowers | Neutral | $11.00 | $12.00 |
| A.J. Rice | UBS | Lowers | Buy | $14.00 | $14.50 |
| Ann Hynes | Mizuho | Lowers | Outperform | $12.00 | $20.00 |
| Benjamin Rossi | JP Morgan | Lowers | Neutral | $12.00 | $15.00 |
| Ann Hynes | Mizuho | Lowers | Outperform | $13.00 | $20.00 |
| Jason Cassorla | Guggenheim | Lowers | Buy | $15.00 | $18.00 |
| Ben Hendrix | RBC Capital | Lowers | Outperform | $16.00 | $21.00 |
| David Macdonald | Truist Securities | Lowers | Buy | $13.00 | $21.00 |
| Scott Fidel | Stephens & Co. | Lowers | Overweight | $17.00 | $21.00 |
| Craig Hettenbach | Morgan Stanley | Lowers | Equal-Weight | $12.00 | $22.00 |
| Kevin Fischbeck | B of A Securities | Lowers | Underperform | $10.00 | $12.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ardent Health. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ardent Health compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Ardent Health's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ardent Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Ardent Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Ardent Health
Ardent Health Inc is a provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in services and technologies, Ardent is passionate about making healthcare easier to access.
Understanding the Numbers: Ardent Health's Finances
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ardent Health displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 8.75%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -1.49%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.88%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ardent Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.46%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ardent Health's debt-to-equity ratio is below the industry average. With a ratio of 1.84, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.